EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy

Maria Ungericht iD, Thomas Schuetz, Moritz Messner, Christian Puelacher, Simon Staggl, Marc-Michael Zaruba, Alexander Stephan Kroiss, Axel Bauer, Gerhard Poelzl

European Journal of Nuclear Medicine and Molecular Imaging · 2025-06 · 52 (7) · 2529-2537

DOI: 10.1007/s00259-025-07092-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 06.02.2025. Verfasst von Maria Ungericht und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. maria.unger…. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Organotechnetium Compounds, Benzoxazoles, Cardiomyopathies. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, University of Innsbruck and Medical University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The relevance of repetitive [ 99m Tc]Tc-DPD scintigraphy in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) remains unclear. We investigated the impact of tafamidis on cardiac [ 99m Tc]Tc-DPD uptake, clinical, and laboratory markers at 6 and 12 months, and correlated 12 months [ 99m Tc]Tc-DPD uptake regression with survival.

Methods

This single-center study enrolled 39 ATTRwt-CM patients. Upon treatment initiation with tafamidis, patients underwent follow-up [ 99m Tc]Tc-DPD scintigraphy, and clinical and laboratory evaluations at 6 months ( n = 6) and 12 months ( n = 13), or both ( n = 20).

Results

Tafamidis resulted in a significant decline in Perugini score (6 months p = 0.008, 12 months p < 0.001), and (semi-)quantitative [ 99m Tc]Tc-DPD uptake (total cardiac uptake: baseline 816 [522–933] cps, vs. 6 months 634 [502–734] cps, p = 0.003, vs. 12 months 523 [108–754] cps, p = 0.001). Clinical and laboratory improvements were observed (NYHA: 6 months p = 0.007, 12 months p = 0.033; NT-proBNP: baseline 2586 [1271–5561] ng/L, vs. 6 months 2526 [1109–4786] ng/L, p = 0.016, vs. 12 months 2340 [1411–4749] ng/L, p = 0.012). In Kaplan–Meier analysis, a decrease in right ventricular [ 99m Tc]Tc-DPD tracer uptake equal to or greater than the median value at 12 months (-30%) was associated with improved survival (log-rank p = 0.021).

Conclusions

Tafamidis in ATTRwt-CM resulted in significant reductions of cardiac [ 99m Tc]Tc-DPD uptake, NYHA class, and cardiac biomarkers at 6 and 12 months. Regression of right ventricular [ 99m Tc]Tc-DPD uptake at 12 months was associated with improved survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialOrganotechnetium CompoundsBenzoxazolesCardiomyopathiesHumansMaleFemaleAgedRadionuclide ImagingMiddle AgedAged, 80 and overRadiopharmaceuticalsDiphosphonates

Stichwörter der Autor:innen

AmyloidosisMonitoringTafamidisTransthyretin[99mTc]Tc-DPD scintigraphy

Substanzen

tafamidisOrganotechnetium CompoundsBenzoxazolestechnetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acidRadiopharmaceuticalsDiphosphonates

Autor:innen und Institutionen

  • Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. maria.ungericht@tirol-kliniken.at.
  • Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria.
  • Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Nuclear Medicine, General Hospital Barmherzige Schwestern, Ried Im Innkreis, Austria.

ORCID-Profile: Maria Ungericht

Förderung

  • Pfizer
  • University of Innsbruck and Medical University of Innsbruck

Zitieren

APA

Ungericht, M., Schuetz, T., Messner, M., Puelacher, C., Staggl, S., Zaruba, M. M., Kroiss, A. S., Bauer, A., & Poelzl, G. (2025). Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging, 52(7), 2529-2537. https://doi.org/10.1007/s00259-025-07092-7

Vancouver

Ungericht M, Schuetz T, Messner M, Puelacher C, Staggl S, Zaruba MM, et al. Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(7):2529-2537. doi:10.1007/s00259-025-07092-7

BibTeX
@article{Ungericht2025,
  author = {Ungericht, Maria and Schuetz, Thomas and Messner, Moritz and Puelacher, Christian and Staggl, Simon and Zaruba, Marc-Michael and Kroiss, Alexander Stephan and Bauer, Axel and Poelzl, Gerhard},
  title = {Effects of tafamidis on serial [99mTc]Tc-DPD scintigraphy in transthyretin amyloid cardiomyopathy},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {7},
  pages = {2529--2537},
  doi = {10.1007/s00259-025-07092-7}
}
Kostenlos starten →